New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The
Go back to New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 215.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $215.50 | 52 Week High | $333.65 | |||
| Open | $215.50 | 52 Week Low | $223.02 | |||
| Day High | $215.50 | P/E | 27.59 | |||
| Day Low | $215.50 | EPS | $7.81 | |||
| Volume | 934 | |||||
